{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T20:31:24Z","timestamp":1791664284284,"version":"4.3.4"},"reference-count":81,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","award":["2U54MD007590-38"],"award-info":[{"award-number":["2U54MD007590-38"]}],"id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000152","name":"Division of Molecular and Cellular Biosciences","doi-asserted-by":"publisher","award":["2401924"],"award-info":[{"award-number":["2401924"]}],"id":[{"id":"10.13039\/100000152","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012127","name":"Augusta University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012127","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cellsig.2026.112368","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:40:27Z","timestamp":1768264827000},"page":"112368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["The YAP1 and EPHA3 receptor tyrosine kinase axis regulates cellular plasticity and treatment response"],"prefix":"10.1016","volume":"141","author":[{"given":"Marwah M.","family":"Al-Mathkour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrahman M.","family":"Dwead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kezhan","family":"Khazaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bekir","family":"Cinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellsig.2026.112368_bb0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrd4175","article-title":"Therapeutic targeting of EPH receptors and their ligands","volume":"13","author":"Boyd","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cellsig.2026.112368_bb0010","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nrm.2015.16","article-title":"Mechanisms of ephrin-Eph signalling in development, physiology and disease","volume":"17","author":"Kania","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.cellsig.2026.112368_bb0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrc2806","article-title":"Eph receptors and ephrins in cancer: bidirectional signalling and beyond","volume":"10","author":"Pasquale","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cellsig.2026.112368_bb0020","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ccr.2013.01.007","article-title":"EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme","volume":"23","author":"Day","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellsig.2026.112368_bb0025","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.3892\/or.2013.2679","article-title":"High levels of EphA3 expression are associated with high invasive capacity and poor overall survival in hepatocellular carcinoma","volume":"30","author":"Lu","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.cellsig.2026.112368_bb0030","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1158\/0008-5472.CAN-18-0267","article-title":"Cotargeting Ephrin receptor tyrosine kinases A2 and A3 in cancer stem cells reduces growth of recurrent glioblastoma","volume":"78","author":"Qazi","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112368_bb0035","doi-asserted-by":"crossref","first-page":"34298","DOI":"10.18632\/oncotarget.16100","article-title":"Epha3 acts as proangiogenic factor in multiple myeloma","volume":"8","author":"Caivano","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.cellsig.2026.112368_bb0040","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/leu.2016.371","article-title":"EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia","volume":"31","author":"Charmsaz","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.cellsig.2026.112368_bb0045","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00535-012-0549-4","article-title":"Aberrant expression of EphA3 in gastric carcinoma: correlation with tumor angiogenesis and survival","volume":"47","author":"Xi","year":"2012","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.cellsig.2026.112368_bb0050","doi-asserted-by":"crossref","DOI":"10.1038\/srep41576","article-title":"Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer","volume":"7","author":"Andretta","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cellsig.2026.112368_bb0055","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1002\/jcb.21926","article-title":"The EphA3 receptor is expressed in a subset of rhabdomyosarcoma cell lines and suppresses cell adhesion and migration","volume":"105","author":"Clifford","year":"2008","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.cellsig.2026.112368_bb0060","doi-asserted-by":"crossref","first-page":"11959","DOI":"10.1007\/s13277-016-5048-4","article-title":"EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K\/BMX\/STAT3 signaling pathway","volume":"37","author":"Peng","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.cellsig.2026.112368_bb0065","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009486","article-title":"EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses","volume":"12","author":"Lertsumitkul","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cellsig.2026.112368_bb0070","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.leukres.2016.09.012","article-title":"KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: results from a phase 1 study","volume":"50","author":"Swords","year":"2016","journal-title":"Leuk. Res."},{"key":"10.1016\/j.cellsig.2026.112368_bb0075","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.leukres.2017.02.007","article-title":"Corrigendum to \u201cKB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study\u201d [Leuk. Res. 50 (Nov) (2016) 123\u2013131. PubMed PMID: 27736729]","volume":"59","author":"Swords","year":"2017","journal-title":"Leuk Res"},{"key":"10.1016\/j.cellsig.2026.112368_bb0080","first-page":"1174","article-title":"Androgen receptor induces EPHA3 expression by interacting with transcription factor SP1","volume":"40","author":"Diao","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.cellsig.2026.112368_bb0085","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.22871","article-title":"The prognosis value of EphA3 and the androgen receptor in prostate cancer treated with radical prostatectomy","volume":"33","author":"Duan","year":"2019","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.cellsig.2026.112368_bb0090","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.cmet.2018.07.010","article-title":"Interplay between YAP\/TAZ and metabolism","volume":"28","author":"Koo","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.cellsig.2026.112368_bb0095","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41580-018-0086-y","article-title":"Hippo-YAP\/TAZ signalling in organ regeneration and regenerative medicine","volume":"20","author":"Moya","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.cellsig.2026.112368_bb0100","first-page":"9","article-title":"YAP\/TAZ as master regulators in cancer: modulation, function and therapeutic approaches","volume":"4","author":"Piccolo","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.cellsig.2026.112368_bb0105","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ydbio.2020.12.018","article-title":"YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance","volume":"475","author":"Szulzewsky","year":"2021","journal-title":"Dev. Biol."},{"key":"10.1016\/j.cellsig.2026.112368_bb0110","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s43018-023-00577-0","article-title":"An allosteric pan-TEAD inhibitor blocks oncogenic YAP\/TAZ signaling and overcomes KRAS G12C inhibitor resistance","volume":"4","author":"Hagenbeek","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.cellsig.2026.112368_bb0115","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.trecan.2019.02.010","article-title":"YAP\/TAZ signaling and resistance to cancer therapy","volume":"5","author":"Nguyen","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.cellsig.2026.112368_bb0120","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.7150\/thno.40889","article-title":"A combat with the YAP\/TAZ-TEAD oncoproteins for cancer therapy","volume":"10","author":"Pobbati","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.cellsig.2026.112368_bb0125","doi-asserted-by":"crossref","first-page":"8126","DOI":"10.1038\/ncomms9126","article-title":"YAP1 and AR interactions contribute to the switch from androgen-dependent to castration-resistant growth in prostate cancer","volume":"6","author":"Kuser-Abali","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2026.112368_bb0130","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.ccell.2015.05.005","article-title":"ERG activates the YAP1 transcriptional program and induces the development of age-related prostate tumors","volume":"27","author":"Nguyen","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellsig.2026.112368_bb0135","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrurol.2015.240","article-title":"Prostate cancer: targetable YAP1-AR interaction key to disease progression","volume":"12","author":"Thoma","year":"2015","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.cellsig.2026.112368_bb0140","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-15-0224","article-title":"Targeting YAP-dependent MDSC infiltration impairs tumor progression","volume":"6","author":"Wang","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cellsig.2026.112368_bb0145","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/path.5781","article-title":"Reciprocal YAP1 loss and INSM1 expression in neuroendocrine prostate cancer","volume":"255","author":"Asrani","year":"2021","journal-title":"J. Pathol."},{"key":"10.1016\/j.cellsig.2026.112368_bb0150","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41391-020-0229-z","article-title":"The expression of YAP1 is increased in high-grade prostatic adenocarcinoma but is reduced in neuroendocrine prostate cancer","volume":"23","author":"Cheng","year":"2020","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.cellsig.2026.112368_bb0155","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1038\/s41388-021-01718-4","article-title":"YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer","volume":"40","author":"Lee","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.cellsig.2026.112368_bb0160","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1038\/s41598-022-07790-4","article-title":"The hippo effector YAP1\/TEAD1 regulates EPHA3 expression to control cell contact and motility","volume":"12","author":"Al-Mathkour","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cellsig.2026.112368_bb0165","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","article-title":"TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112368_bb0170","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.cellsig.2026.112368_bb0175","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cellsig.2026.112368_bb0180","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"10.1016\/j.cellsig.2026.112368_bb0185","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1158\/0008-5472.CAN-16-0902","article-title":"Integrated classification of prostate cancer reveals a novel luminal subtype with poor outcome","volume":"76","author":"You","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112368_bb0190","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/s41467-021-21860-7","article-title":"A noncanonical AR addiction drives enzalutamide resistance in prostate cancer","volume":"12","author":"He","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2026.112368_bb0195","doi-asserted-by":"crossref","DOI":"10.4161\/sgtp.29846","article-title":"Rho-associated coiled-coil containing kinases (ROCK): structure, regulation, and functions","volume":"5","author":"Julian","year":"2014","journal-title":"Small GTPases"},{"key":"10.1016\/j.cellsig.2026.112368_bb0200","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.nbd.2017.09.005","article-title":"ERK and ROCK functionally interact in a signaling network that is compensationally upregulated in spinal muscular atrophy","volume":"108","author":"Hensel","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.cellsig.2026.112368_bb0205","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S1535-6108(03)00162-4","article-title":"ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility","volume":"4","author":"Vial","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellsig.2026.112368_bb0210","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/40187","article-title":"Calcium sensitization of smooth muscle mediated by a rho-associated protein kinase in hypertension","volume":"389","author":"Uehata","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2026.112368_bb0215","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.7150\/thno.34700","article-title":"Overcoming EZH2 inhibitor resistance by Taxane in PTEN-mutated cancer","volume":"9","author":"Ma","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.cellsig.2026.112368_bb0220","doi-asserted-by":"crossref","DOI":"10.1038\/srep42138","article-title":"Human embryonic and induced pluripotent stem cells maintain phenotype but alter their metabolism after exposure to ROCK inhibitor","volume":"7","author":"Vernardis","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cellsig.2026.112368_bb0225","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41467-022-28319-3","article-title":"ROCK1 mechano-signaling dependency of human malignancies driven by TEAD\/YAP activation","volume":"13","author":"Esposito","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2026.112368_bb0230","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41580-021-00442-x","article-title":"The many regulators of epithelial-mesenchymal transition","volume":"23","author":"Bracken","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.cellsig.2026.112368_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021650","article-title":"TMPRSS2\/ERG promotes epithelial to mesenchymal transition through the ZEB1\/ZEB2 axis in a prostate cancer model","volume":"6","author":"Leshem","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.cellsig.2026.112368_bb0240","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1053\/j.gastro.2020.12.077","article-title":"Zinc-dependent regulation of ZEB1 and YAP1 coactivation promotes epithelial-mesenchymal transition plasticity and metastasis in pancreatic cancer","volume":"160","author":"Liu","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cellsig.2026.112368_bb0245","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41467-023-44210-1","article-title":"Distinct mesenchymal cell states mediate prostate cancer progression","volume":"15","author":"Pakula","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2026.112368_bb0250","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/stmcls\/sxae025","article-title":"Stem cell dynamics and cellular heterogeneity across lineage subtypes of castrate-resistant prostate cancer","volume":"42","author":"Beshiri","year":"2024","journal-title":"Stem Cells"},{"key":"10.1016\/j.cellsig.2026.112368_bb0255","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/s41416-018-0291-7","article-title":"CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer","volume":"119","author":"Ooki","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cellsig.2026.112368_bb0260","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.cellsig.2026.112368_bb0265","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1172\/JCI128212","article-title":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","volume":"129","author":"Labrecque","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellsig.2026.112368_bb0270","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41585-021-00438-4","article-title":"Resistance to second-generation androgen receptor antagonists in prostate cancer","volume":"18","author":"Schmidt","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.cellsig.2026.112368_bb0275","doi-asserted-by":"crossref","DOI":"10.1126\/science.abe1505","article-title":"Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets","volume":"376","author":"Tang","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.cellsig.2026.112368_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/cells8040370","article-title":"The hippo pathway in prostate cancer","volume":"8","author":"Salem","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.cellsig.2026.112368_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184590","article-title":"Mapping the STK4\/hippo signaling network in prostate cancer cell","volume":"12","author":"Ready","year":"2017","journal-title":"PloS One"},{"key":"10.1016\/j.cellsig.2026.112368_bb0290","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellsig.2026.112368_bb0295","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ceb.2007.08.004","article-title":"Cell-cell signaling via Eph receptors and ephrins","volume":"19","author":"Himanen","year":"2007","journal-title":"Curr. Opin. Cell Biol."},{"key":"10.1016\/j.cellsig.2026.112368_bb0300","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.21037\/atm-21-6191","article-title":"A comprehensive characterization of the transcriptome in enzalutamide resistance prostate cancer","volume":"9","author":"Wang","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.cellsig.2026.112368_bb0305","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1128\/MCB.00102-15","article-title":"The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells","volume":"35","author":"Zhang","year":"2015","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.cellsig.2026.112368_bb0310","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.7150\/thno.56604","article-title":"MYBL2 disrupts the hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer","volume":"11","author":"Li","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.cellsig.2026.112368_bb0315","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1002\/jcp.30759","article-title":"NF-\u03baB as a regulator of cancer metastasis and therapy response: a focus on epithelial-mesenchymal transition","volume":"237","author":"Mirzaei","year":"2022","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.cellsig.2026.112368_bb0320","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019103209","article-title":"Genome-wide cooperation of EMT transcription factor ZEB1 with YAP and AP-1 in breast cancer","volume":"39","author":"Feldker","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.cellsig.2026.112368_bb0325","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10498","article-title":"ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types","volume":"7","author":"Lehmann","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2026.112368_bb0330","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.bbrc.2018.06.140","article-title":"Ephrin-B3 binds both cell-associated and secreted proteoglycans","volume":"503","author":"Prydz","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.cellsig.2026.112368_bb0335","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/path.2220","article-title":"CD44-positive colorectal adenoma cells express the potential stem cell markers musashi antigen (msi1) and ephrin B2 receptor (EphB2)","volume":"213","author":"Schulenburg","year":"2007","journal-title":"J. Pathol."},{"key":"10.1016\/j.cellsig.2026.112368_bb0340","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5732\/cjc.013.10108","article-title":"The role of EPH receptors in cancer-related epithelial-mesenchymal transition","volume":"33","author":"Li","year":"2014","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.cellsig.2026.112368_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216479","article-title":"Claudin-1 interacts with EPHA2 to promote cancer stemness and chemoresistance in colorectal cancer","volume":"579","author":"Primeaux","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.cellsig.2026.112368_bb0350","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13045-018-0605-5","article-title":"The biology and role of CD44 in cancer progression: therapeutic implications","volume":"11","author":"Chen","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.cellsig.2026.112368_bb0355","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/s41598-020-80060-3","article-title":"Ephrin A4-ephrin receptor A10 signaling promotes cell migration and spheroid formation by upregulating NANOG expression in oral squamous cell carcinoma cells","volume":"11","author":"Chen","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cellsig.2026.112368_bb0360","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.biopha.2018.03.042","article-title":"Standard CD44 modulates YAP1 through a positive feedback loop in hepatocellular carcinoma","volume":"103","author":"Fan","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.cellsig.2026.112368_bb0365","article-title":"Fluid shear stress activates YAP1 to promote cancer cell motility","volume":"8","author":"Lee","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cellsig.2026.112368_bb0370","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1096\/fba.2021-00055","article-title":"RhoA-ROCK competes with YAP to regulate amoeboid breast cancer cell migration in response to lymphatic-like flow","volume":"4","author":"Mohammadalipour","year":"2022","journal-title":"FASEB Bioadv"},{"key":"10.1016\/j.cellsig.2026.112368_bb0375","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1101\/gad.315127.118","article-title":"A RhoA-YAP-c-Myc signaling axis promotes the development of polycystic kidney disease","volume":"32","author":"Cai","year":"2018","journal-title":"Genes Dev."},{"key":"10.1016\/j.cellsig.2026.112368_bb0380","article-title":"YAP1 recognizes inflammatory and mechanical cues to exacerbate benign prostatic hyperplasia via promoting cell survival and fibrosis","volume":"11","author":"Lin","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.cellsig.2026.112368_bb0385","article-title":"Targeting ROCK1\/YAP1 Axis ameliorates inflammation-induced prostatic hyperplasia via Stabilising SIRT1-dependent mitochondrial dynamics","author":"Lin","year":"2025","journal-title":"Cell Prolif."},{"key":"10.1016\/j.cellsig.2026.112368_bb0390","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13046-022-02354-w","article-title":"SEMA6A\/RhoA\/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF\/MEK inhibition in BRAF-mutant melanoma","volume":"41","author":"Loria","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.cellsig.2026.112368_bb0395","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2018.0229","article-title":"Mechanotransduction: from the cell surface to the nucleus via RhoA","volume":"374","author":"Burridge","year":"2019","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.cellsig.2026.112368_bb0400","doi-asserted-by":"crossref","DOI":"10.3390\/cells5020017","article-title":"The regulation of cellular responses to mechanical cues by rho GTPases","volume":"5","author":"Hoon","year":"2016","journal-title":"Cells"},{"key":"10.1016\/j.cellsig.2026.112368_bb0405","first-page":"722","article-title":"EphA3 inhibits migration and invasion of esophageal cancer cells by activating the mesenchymal-epithelial transition process","volume":"54","author":"Chen","year":"2019","journal-title":"Int. J. Oncol."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656826000173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656826000173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:41:58Z","timestamp":1776825718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656826000173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":81,"alternative-id":["S0898656826000173"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2026.112368","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The YAP1 and EPHA3 receptor tyrosine kinase axis regulates cellular plasticity and treatment response","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2026.112368","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"112368"}}